- Home
- TENB vs DAWN Comparison
TENB vs DAWN Comparison
Compare TENB & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | DAWN |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TENB | DAWN |
|---|---|---|
| Price | $25.43 | $21.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $31.69 | $24.43 |
| AVG Volume (30 Days) | ★ 3.3M | 2.4M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.23 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $999,405,000.00 | $158,182,000.00 |
| Revenue This Year | $9.37 | $55.03 |
| Revenue Next Year | $7.04 | $28.12 |
| P/E Ratio | $2,522.00 | ★ N/A |
| Revenue Growth | 11.04 | ★ 20.60 |
| 52 Week Low | $15.73 | $5.64 |
| 52 Week High | $35.69 | $21.53 |
Technical Indicators
Market Signals| Indicator | TENB | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 75.51 | 80.29 |
| Support Level | $22.03 | $10.30 |
| Resistance Level | $30.79 | N/A |
| Average True Range (ATR) | 1.23 | 0.03 |
| MACD | 0.40 | -0.28 |
| Stochastic Oscillator | 90.77 | 90.91 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.